PHREESIA INC (PHR) Stock Fundamental Analysis
NYSE:PHR - US71944F1066 - Common Stock
29.75 USD
+0.99 (+3.44%)
29.75 USD
0 (0%)
Taking everything into account, PHR scores 4 out of 10 in our fundamental rating. PHR was compared to 35 industry peers in the Health Care Technology industry. PHR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHR has reported negative net income.
PHR had a positive operating cash flow in the past year.
PHR had negative earnings in each of the past 5 years.
In multiple years PHR reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of PHR (-10.67%) is better than 61.11% of its industry peers.
The Return On Equity of PHR (-15.14%) is better than 63.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.67% | ||
| ROE | -15.14% | ||
| ROIC | N/A |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHR has a Gross Margin of 68.02%. This is in the better half of the industry: PHR outperforms 72.22% of its industry peers.
PHR's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for PHR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PHR has more shares outstanding
The debt/assets ratio for PHR is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.22 indicates that PHR is not in any danger for bankruptcy at the moment.
The Altman-Z score of PHR (7.22) is better than 86.11% of its industry peers.
PHR has a debt to FCF ratio of 0.66. This is a very positive value and a sign of high solvency as it would only need 0.66 years to pay back of all of its debts.
The Debt to FCF ratio of PHR (0.66) is better than 80.56% of its industry peers.
PHR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
PHR has a Debt to Equity ratio of 0.02. This is in the better half of the industry: PHR outperforms 61.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.66 | ||
| Altman-Z | 7.22 |
ROIC/WACCN/A
WACC10.25%
2.3 Liquidity
A Current Ratio of 1.95 indicates that PHR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.95, PHR is in line with its industry, outperforming 50.00% of the companies in the same industry.
A Quick Ratio of 1.95 indicates that PHR should not have too much problems paying its short term obligations.
PHR has a Quick ratio (1.95) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.95 |
3. Growth
3.1 Past
PHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.65%, which is quite impressive.
Looking at the last year, PHR shows a quite strong growth in Revenue. The Revenue has grown by 16.29% in the last year.
Measured over the past years, PHR shows a very strong growth in Revenue. The Revenue has been growing by 27.46% on average per year.
EPS 1Y (TTM)35.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)16.29%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.54%
3.2 Future
Based on estimates for the next years, PHR will show a very strong growth in Earnings Per Share. The EPS will grow by 38.94% on average per year.
PHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.19% yearly.
EPS Next Y85.52%
EPS Next 2Y49.7%
EPS Next 3Y38.94%
EPS Next 5YN/A
Revenue Next Year13.81%
Revenue Next 2Y12.69%
Revenue Next 3Y12.38%
Revenue Next 5Y12.19%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHR. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 120.97, PHR can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHR is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 22.81. PHR is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 120.97 |
4.2 Price Multiples
PHR's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 80.76 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PHR's earnings are expected to grow with 38.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.7%
EPS Next 3Y38.94%
5. Dividend
5.1 Amount
No dividends for PHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
29.75
+0.99 (+3.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners96.06%
Inst Owner Change4.35%
Ins Owners4.73%
Ins Owner Change0.43%
Market Cap1.77B
Analysts85.26
Price Target32.88 (10.52%)
Short Float %5.12%
Short Ratio5.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.24%
Min EPS beat(2)38.81%
Max EPS beat(2)41.66%
EPS beat(4)4
Avg EPS beat(4)25.79%
Min EPS beat(4)8.94%
Max EPS beat(4)41.66%
EPS beat(8)8
Avg EPS beat(8)25.32%
EPS beat(12)12
Avg EPS beat(12)23.1%
EPS beat(16)14
Avg EPS beat(16)4.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.24%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)-0.18%
Revenue beat(4)0
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-0.59%
Max Revenue beat(4)-0.18%
Revenue beat(8)2
Avg Revenue beat(8)-0.12%
Revenue beat(12)6
Avg Revenue beat(12)0.6%
Revenue beat(16)10
Avg Revenue beat(16)1.9%
PT rev (1m)0.24%
PT rev (3m)-0.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.29%
EPS NY rev (1m)0%
EPS NY rev (3m)34.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 120.97 | ||
| P/S | 4.07 | ||
| P/FCF | 80.76 | ||
| P/OCF | 36.91 | ||
| P/B | 6.27 | ||
| P/tB | 14.1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.74
EYN/A
EPS(NY)0.25
Fwd EY0.83%
FCF(TTM)0.37
FCFY1.24%
OCF(TTM)0.81
OCFY2.71%
SpS7.3
BVpS4.74
TBVpS2.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.67% | ||
| ROE | -15.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% | ||
| FCFM | 5.04% |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
F-Score7
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.66 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 92.68% | ||
| Cap/Sales | 5.99% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.95 | ||
| Altman-Z | 7.22 |
F-Score7
WACC10.25%
ROIC/WACCN/A
Cap/Depr(3y)91.68%
Cap/Depr(5y)107.3%
Cap/Sales(3y)7.37%
Cap/Sales(5y)9.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y85.52%
EPS Next 2Y49.7%
EPS Next 3Y38.94%
EPS Next 5YN/A
Revenue 1Y (TTM)16.29%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.54%
Revenue Next Year13.81%
Revenue Next 2Y12.69%
Revenue Next 3Y12.38%
Revenue Next 5Y12.19%
EBIT growth 1Y64.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year245.92%
EBIT Next 3Y64.12%
EBIT Next 5Y36.17%
FCF growth 1Y122.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y168.36%
OCF growth 3YN/A
OCF growth 5Y108.09%